March 27, 2026

The Influence of Lymph Node Architecture on Lymphoma

The Influence of Lymph Node Architecture on Lymphoma

For the first time, researchers have succeeded in mapping the organization of immune cells in human lymph nodes. The study was led by scientists from Heinrich Heine University Düsseldorf, Düsseldorf University Hospital, the German Cancer Research Center (DKFZ), the European Molecular Biology Laboratory (EMBL), and the Max Delbrück Center (MDC) in Berlin. They were able to demonstrate why the architecture of healthy lymph nodes is altered in malignant lymphomas.

Tissue section through a lymph node (C) Wikipedia/Ed Uthman, MD

Lymph nodes are central hubs of the immune system and play a vital role in defending against infections and tumors. For this to function properly, immune cells (B cells and T cells) must be precisely organized spatially within the lymph node tissue, for example in so-called B-cell follicles and T-cell zones. This is controlled by stromal cells (non-hematopoietic supporting cells). They release signaling molecules, thereby generating guidance signals that immune cells use to find their designated locations within the lymph node.

In B-cell lymphomas, the internal organization of the lymph node tissue is disrupted in very different ways depending on the disease: While in slow-growing lymphomas, such as follicular lymphoma (FL), the basic tissue structure remains intact, the spatial organization in aggressive lymphomas, such as diffuse large B-cell lymphoma (DLBCL), breaks down completely. Why these typical growth patterns arise has been largely unclear until now.

In the current study, the researchers succeeded for the first time in systematically mapping these processes in human lymph nodes. Using single-cell analyses and spatial tissue mapping, they were able to trace which factors cause the lymph node architecture to increasingly disintegrate in lymphoma diseases.

The data show that stromal cells are the “architects” of the lymph node. The researchers were able to demonstrate that key signaling pathways in specialized stromal cells undergo fundamental changes in lymphoma, causing the spatial organization of the lymph node to gradually collapse. These changes in stromal cells are reflected in the growth patterns of lymphomas: While in FL the relative sizes of B-cell follicles and T-cell zones shift, the areas remain largely spatially separated; in DLBCL, however, key regulatory signals—and thus the tissue structure—are largely lost.

The study identifies an inflammatory vicious cycle as the driving mechanism: As part of the immune response in the tumor microenvironment, T cells produce pro-inflammatory signaling molecules, known as interferons, which cause stromal cells to switch their production of signaling molecules (chemokines): Instead of structure-defining signals, inflammatory chemokines dominate, which in turn attract further inflammatory cells. The loss of lymph node organization in lymphomas is therefore not a passive effect of tumor growth, but is actively driven by inflammatory processes in the tumor microenvironment.

In patients, this reprogramming of stromal cells is associated with poorer survival outcomes. The researchers were able to demonstrate in large patient cohorts that a loss of structuring chemokines is associated with an unfavorable prognosis.

These findings also open the door to new potential therapeutic approaches. “Our results could be very important for the development of new therapies and diagnostic procedures,” said Daniel Hübschmann of the DKFZ.

Source: Press release from the University Hospital Düsseldorf

Publication:
Felix Czernilofsky et al.: Reprogramming of stroma-derived chemokine networks drives the loss of tissue organization in nodal B-cell lymphoma
Nature Cancer 2026, DOI: 10.1038/s43018-026-01136-z

Our latest News

discover more
Vaccine Against Brain Tumors Shows Promising Long-Term Results

Vaccine Against Brain Tumors Shows Promising Long-Term Results

A novel vaccination strategy against certain malignant brain tumors could fundamentally improve treatment for patients. Researchers from the German Cancer Research Center (DKFZ), Mannheim University Medical Center, Heidelberg University Hospital, and numerous partner institutions* have published encouraging long-term results from a clinical trial involving a vaccine that activates the immune system against a common genetic […]

VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering

VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering

The next-generation platform integrates VectorBuilder’s regulatory-compliant gene delivery technology with MaxCyte’s clinically validated electroporation platform to enable robust, scalable, and reliable clinical-grade cell engineering. Chicago, IL & Rockville, MD – June 23, 2026 – VectorBuilder, a global leader in gene delivery technologies and CDMO services, and MaxCyte, a leading, cell-engineering company providing enabling platform technologies to […]

LEEI-Platform eFIT is Available to Industry and Research

LEEI-Platform eFIT is Available to Industry and Research

KyooBe Tech is making its innovative vaccine development platform available to industry and research partners:Enabling faster and scalable vaccine production using Low-Energy Electron Irradiation (LEEI). Flexible Vaccine Manufacturing for Emerging Infectious Diseases Recent infectious disease events—from hantavirus outbreaks and meningitis cases to recurring disease outbreaks in livestock farming—highlight the need for flexibly scalable vaccine manufacturing […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp